Literature DB >> 10960841

Vascular endothelial growth factor content in metastasizing and nonmetastasizing Dunning prostatic adenocarcinoma.

S Häggström1, A Bergh, J E Damber.   

Abstract

BACKGROUND: Tumor angiogenesis is important in progressive tumor growth and metastasis. In the normal rat prostate and in androgen-sensitive prostate tumors androgen ablation causes an involution of the vasculature and a decrease in the vascular endothelial growth factor (VEGF) levels before regression of the prostate gland. To examine whether angiogenesis and metastasis are regulated by VEGF in androgen-insensitive and metastasizing prostate tumors, five Dunning rat prostate cancer sublines were tested; the androgen-sensitive, nonmetastasizing R3327 PAP, and the androgen-insensitive, low metastasizing AT-1, and the three androgen-insensitive, metastasizing AT-2, AT-3, and MatLyLu Dunning prostatic adenocarcinomas.
METHODS: VEGF levels were quantified in the rat dorsolateral prostate and in the five Dunning sublines using competitive RT-PCR, Western blot, and Elisa. Vascular density was determined by factor VIII staining.
RESULTS: VEGF mRNA was increased in all tumors compared with normal prostates. The two metastatic sublines AT-3 and MatLyLu and the nonmetastatic subline AT-1 showed the highest VEGF mRNA expression. VEGF protein levels in the prostate gland showed increased expression in the metastatic sublines, AT-2, AT-3, and MatLyLu, compared with the nonmetastatic AT-1 subline and the ventral prostate. VEGF proteins in serum were highest in the metastatic AT-3 subline. The vessel density was highest in the two highly metastatic sublines AT-3 and MatLyLu.
CONCLUSIONS: Our results suggest that VEGF levels are associated with microvessel density and the previously established metastatic pattern of these rat prostate tumor systems. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10960841     DOI: 10.1002/1097-0045(20000915)45:1<42::aid-pros5>3.0.co;2-e

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  7 in total

1.  Angiotensin-(1-7) attenuates metastatic prostate cancer and reduces osteoclastogenesis.

Authors:  Bhavani Krishnan; Thomas L Smith; Purnima Dubey; Michael E Zapadka; Frank M Torti; Mark C Willingham; E Ann Tallant; Patricia E Gallagher
Journal:  Prostate       Date:  2012-05-29       Impact factor: 4.104

2.  Inhibition of angiopoietin-2 in LuCaP 23.1 prostate cancer tumors decreases tumor growth and viability.

Authors:  Colm Morrissey; Alex Dowell; Theodore D Koreckij; Holly Nguyen; Bryce Lakely; William C Fanslow; Lawrence D True; Eva Corey; Robert L Vessella
Journal:  Prostate       Date:  2010-12-01       Impact factor: 4.104

3.  Vascular endothelial growth factor-mediated autocrine stimulation of prostate tumor cells coincides with progression to a malignant phenotype.

Authors:  S Soker; M Kaefer; M Johnson; M Klagsbrun; A Atala; M R Freeman
Journal:  Am J Pathol       Date:  2001-08       Impact factor: 4.307

4.  Correlation of vascular endothelial growth factor expression with fibroblast growth factor-8 expression and clinico-pathologic parameters in human prostate cancer.

Authors:  A F West; M O'Donnell; R G Charlton; D E Neal; H Y Leung
Journal:  Br J Cancer       Date:  2001-08-17       Impact factor: 7.640

Review 5.  Cross Talk Between Macrophages and Cancer Cells in the Bone Metastatic Environment.

Authors:  Lena Batoon; Laurie K McCauley
Journal:  Front Endocrinol (Lausanne)       Date:  2021-11-03       Impact factor: 5.555

6.  Where is VEGF in the body? A meta-analysis of VEGF distribution in cancer.

Authors:  C Kut; F Mac Gabhann; A S Popel
Journal:  Br J Cancer       Date:  2007-10-02       Impact factor: 7.640

7.  A Unique Cellular and Molecular Microenvironment Is Present in Tertiary Lymphoid Organs of Patients with Spontaneous Prostate Cancer Regression.

Authors:  María de la Luz García-Hernández; Norma Ofelia Uribe-Uribe; Ricardo Espinosa-González; W Martin Kast; Shabaana A Khader; Javier Rangel-Moreno
Journal:  Front Immunol       Date:  2017-05-17       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.